StockWatch
·
Medical Specialities
Quarterly ResultAug 6, 2026, 09:04 AM

Aclarion Q2 Net Loss $2.75M; Revenue $25.2K

AI Summary

Aclarion, Inc. reported a net loss of $(2.75) million for the second quarter of 2026, an increase from $(1.60) million in the same period last year. Revenue for the quarter grew to $25,208. For the six months ended June 30, 2026, the company's net loss was $(5.60) million. The company's cash and cash equivalents increased to $16.29 million, partly due to a registered direct offering that raised approximately $10.4 million in gross proceeds, and management believes current cash will fund operations for at least twelve months.

Key Highlights

  • Net loss for the three months ended June 30, 2026, was $(2,747,551) compared to $(1,600,757) in the prior year period.
  • Revenue for the three months ended June 30, 2026, increased to $25,208 from $19,319 in the same period last year.
  • Net loss per share allocable to common stockholders for Q2 2026 was $(1.12) compared to $(2.75) in Q2 2025.
  • Cash and cash equivalents totaled $16,285,462 as of June 30, 2026, up from $12,015,789 at December 31, 2025.
  • Total assets as of June 30, 2026, were $18,039,654, an increase from $13,672,404 at December 31, 2025.
  • Total stockholders' equity stood at $17,002,720 as of June 30, 2026.
  • The company completed a registered direct offering, generating approximately $10.4 million in gross proceeds.
  • Net cash used in operating activities for the six months ended June 30, 2026, was $(5,298,896).